Mr. Neil Kumar, PhD's most recent trade in BridgeBio Pharma Inc was a trade of 14,337 shares done at an average price of $68.5 . Disclosure was reported to the exchange on March 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.48 per share. | 12 Mar 2026 | 14,337 | 661,349 (0%) | 0% | 68.5 | 981,809 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.47 per share. | 12 Mar 2026 | 13,885 | 4,464,562 (3%) | 0% | 68.5 | 950,687 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.20 per share. | 12 Mar 2026 | 10,310 | 635,686 (0%) | 0% | 69.2 | 713,449 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.39 per share. | 12 Mar 2026 | 10,241 | 4,448,206 (3%) | 0% | 68.4 | 700,345 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.23 per share. | 12 Mar 2026 | 9,759 | 4,438,447 (3%) | 0% | 69.2 | 675,568 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 68.36 per share. | 12 Mar 2026 | 9,690 | 645,996 (0%) | 0% | 68.4 | 662,441 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.29 per share. | 12 Mar 2026 | 5,815 | 4,458,747 (3%) | 0% | 69.3 | 402,929 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.32 per share. | 12 Mar 2026 | 5,363 | 655,986 (0%) | 0% | 69.3 | 371,750 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.15 per share. | 12 Mar 2026 | 300 | 655,686 (0%) | 0% | 70.2 | 21,045 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.15 per share. | 12 Mar 2026 | 300 | 4,458,447 (3%) | 0% | 70.2 | 21,045 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.03 per share. | 19 Feb 2026 | 18,923 | 243,581 (0%) | 0% | 71.0 | 1,344,190 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.08 per share. | 19 Feb 2026 | 8,528 | 235,053 (0%) | 0% | 72.1 | 614,702 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.80 per share. | 19 Feb 2026 | 602 | 234,451 (0%) | 0% | 72.8 | 43,826 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 33,544 | 262,320 (0%) | 0% | - | - | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.25 per share. | 16 Feb 2026 | 30,970 | 262,504 (0%) | 0% | 75.3 | 2,330,493 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 19,600 | 281,920 (0%) | 0% | - | - | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2026 | 11,554 | 293,474 (0%) | 0% | - | - | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.80 per share. | 10 Feb 2026 | 14,201 | 701,485 (0%) | 0% | 71.8 | 1,019,657 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.80 per share. | 10 Feb 2026 | 14,040 | 4,504,407 (3%) | 0% | 71.8 | 1,008,006 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.70 per share. | 10 Feb 2026 | 7,860 | 4,490,587 (3%) | 0% | 70.7 | 555,706 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.69 per share. | 10 Feb 2026 | 7,806 | 687,880 (0%) | 0% | 70.7 | 551,796 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.27 per share. | 10 Feb 2026 | 5,960 | 4,498,447 (3%) | 0% | 72.3 | 430,751 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.28 per share. | 10 Feb 2026 | 5,799 | 695,686 (0%) | 0% | 72.3 | 419,165 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.63 per share. | 10 Feb 2026 | 4,484 | 679,680 (0%) | 0% | 72.6 | 325,695 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 72.65 per share. | 10 Feb 2026 | 4,404 | 4,482,408 (3%) | 0% | 72.6 | 319,938 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.25 per share. | 10 Feb 2026 | 3,994 | 675,686 (0%) | 0% | 73.3 | 292,574 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.25 per share. | 10 Feb 2026 | 3,961 | 4,478,447 (3%) | 0% | 73.3 | 290,145 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.46 per share. | 10 Feb 2026 | 3,775 | 4,486,812 (3%) | 0% | 71.5 | 269,754 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.44 per share. | 10 Feb 2026 | 3,716 | 684,164 (0%) | 0% | 71.4 | 265,477 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.65 per share. | 08 Jan 2026 | 11,565 | 4,546,882 (3%) | 0% | 73.7 | 851,811 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 73.64 per share. | 08 Jan 2026 | 11,515 | 744,171 (0%) | 0% | 73.6 | 848,018 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.46 per share. | 08 Jan 2026 | 10,677 | 4,520,302 (3%) | 0% | 77.5 | 827,016 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.61 per share. | 08 Jan 2026 | 10,519 | 716,061 (0%) | 0% | 77.6 | 816,365 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.38 per share. | 08 Jan 2026 | 8,135 | 4,538,747 (3%) | 0% | 74.4 | 605,061 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.38 per share. | 08 Jan 2026 | 8,085 | 736,086 (0%) | 0% | 74.4 | 601,340 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.72 per share. | 08 Jan 2026 | 6,955 | 726,580 (0%) | 0% | 76.7 | 533,569 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 76.53 per share. | 08 Jan 2026 | 6,067 | 4,530,979 (3%) | 0% | 76.5 | 464,289 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.75 per share. | 08 Jan 2026 | 2,151 | 733,535 (0%) | 0% | 75.8 | 162,943 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.10 per share. | 08 Jan 2026 | 1,855 | 4,518,447 (3%) | 0% | 78.1 | 144,882 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.61 per share. | 08 Jan 2026 | 1,401 | 4,537,046 (3%) | 0% | 75.6 | 105,928 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.16 per share. | 08 Jan 2026 | 400 | 735,686 (0%) | 0% | 75.2 | 30,064 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.19 per share. | 08 Jan 2026 | 375 | 715,686 (0%) | 0% | 78.2 | 29,322 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.20 per share. | 08 Jan 2026 | 300 | 4,538,447 (3%) | 0% | 75.2 | 22,561 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2023 | 102,249 | 4,915,446 (3%) | 0% | - | - | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 29.10 per share. | 16 Nov 2023 | 51,352 | 4,813,397 (3%) | 0% | 29.1 | 1,494,128 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.86 per share. | 16 Nov 2023 | 50,697 | 4,864,749 (3%) | 0% | 28.9 | 1,463,115 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 29.55 per share. | 16 Nov 2023 | 200 | 4,813,197 (3%) | 0% | 29.6 | 5,910 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2023 | 102,250 | 4,915,447 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Aug 2023 | 61,182 | 122,364 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 16 Aug 2023 | 51,552 | 4,813,197 (3%) | 0% | 28.6 | 1,473,784 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.80 per share. | 16 Aug 2023 | 50,698 | 4,864,749 (3%) | 0% | 29.8 | 1,510,800 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Aug 2023 | 33,544 | 469,616 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Aug 2023 | 5,130 | 15,388 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Aug 2023 | 2,394 | 14,365 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 102,249 | 4,915,446 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 May 2023 | 61,182 | 183,546 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.01 per share. | 16 May 2023 | 51,552 | 4,813,197 (3%) | 0% | 14.0 | 722,218 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.09 per share. | 16 May 2023 | 50,697 | 4,864,749 (3%) | 0% | 14.1 | 714,321 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 May 2023 | 33,544 | 503,160 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 May 2023 | 5,129 | 20,518 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 May 2023 | 2,394 | 16,759 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 14.18 per share. | 03 May 2023 | 120,000 | 1,012,722 (0%) | 0% | 14.2 | 1,701,744 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 15.46 per share. | 05 Apr 2023 | 120,000 | 1,132,722 (0%) | 0% | 15.5 | 1,855,656 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 10.96 per share. | 03 Mar 2023 | 120,000 | 1,252,722 (1%) | 0% | 11.0 | 1,315,224 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 68,706 | 4,881,903 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Feb 2023 | 61,182 | 244,728 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 12.70 per share. | 16 Feb 2023 | 44,798 | 4,813,197 (3%) | 0% | 12.7 | 569,073 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.64 per share. | 16 Feb 2023 | 23,908 | 4,857,995 (3%) | 0% | 12.6 | 302,197 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Feb 2023 | 5,129 | 25,647 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Feb 2023 | 2,395 | 19,153 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 11.01 per share. | 03 Feb 2023 | 120,000 | 1,372,722 (1%) | 0% | 11.0 | 1,320,696 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 7.67 per share. | 05 Jan 2023 | 120,000 | 1,492,722 (1%) | 0% | 7.7 | 920,856 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 21 Dec 2022 | 200,000 | 995,686 (0%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2022 | 68,706 | 4,881,903 (3%) | 0% | - | - | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Sale of securities on an exchange or to another person at price $ 9.40 per share. | 16 Nov 2022 | 34,640 | 4,813,197 (3%) | 0% | 9.4 | 325,606 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.64 per share. | 16 Nov 2022 | 34,066 | 4,847,837 (3%) | 0% | 9.6 | 328,396 | - |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2022 | 68,705 | 4,840,894 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Aug 2022 | 61,182 | 367,092 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.08 per share. | 16 Aug 2022 | 27,697 | 4,813,197 (3%) | 0% | 11.1 | 306,883 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Aug 2022 | 5,129 | 35,906 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Aug 2022 | 2,394 | 23,942 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 68,705 | 4,795,948 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 May 2022 | 61,182 | 428,274 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.74 per share. | 16 May 2022 | 23,759 | 4,772,189 (3%) | 0% | 6.7 | 160,136 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 May 2022 | 5,129 | 41,035 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 May 2022 | 2,394 | 26,336 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Mar 2022 | 489,456 | 489,456 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2022 | 7,524 | 4,730,328 (3%) | 0% | - | Common Stock | |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Feb 2022 | 5,130 | 46,164 | - | - | Restricted Stock Units | ||
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.84 per share. | 16 Feb 2022 | 3,085 | 4,727,243 (3%) | 0% | 8.8 | 27,271 | Common Stock |
| BridgeBio Pharma Inc | Mr. Neil Kumar, PhD | Director, CEO and President | 16 Feb 2022 | 2,394 | 28,730 | - | - | Restricted Stock Units |